Page 13 - Johnson Medtech News Today

(BPT) - Around the world, about 1 billion people suffer from eye conditions that could be prevented or need to be addressed1. For instance, cataracts are the leading cause of preventable blindness …

Innovative investigational device designed for Left Atrial Appendage Elimination to reduce the risk of stroke in patients with non-valvular atrial fibrillation Strengthens position in high-growth...

Johnson & Johnson MedTech announced today that it completed the acquisition of left atrial appendage (LAA) device maker Laminar.

Healthcare major Johnson & Johnson (JNJ) announced on Thursday that its unit Johnson & Johnson MedTech has completed the acquisition of Laminar, Inc., a privately held medical devices company.

/PRNewswire/ -- Santé Ventures (Santé), an early-stage healthcare and life sciences investment firm, has announced the acquisition of its Fund III portfolio...

In its fifth year, the 40 Under 40 program celebrates the industry’s most highly regarded young talent.

First trial in AMI cardiogenic shock to use the FDA’s EFIC protocol  

Abiomed, part of Johnson & Johnson MedTech, announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT).

DANVERS — Abiomed, part of Johnson & Johnson MedTech, hosted its annual Thanksgiving luncheon for employees on Tuesday, Nov. 14. Members of Abiomed’s executive team served more than 1,000 employees

Partnership will prioritise addressing health inequalities in the region